Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


New enterprise plan at UCL aims for 500 new companies

21 July 2011

[image reference is broken]

UCL is launching a five-year campaign to boost the role of enterprise at the university.

The ambitious aims include doubling income from licensing, sponsored research and other key commercial activities; creating 500 new enterprises on- and off-campus; offering courses in entrepreneurship to all students and training for staff; and providing sabbatical leave for academics involved in innovation.

“Being enterprising and having a broad portfolio of enterprise activities is central to the core mission of a university. And a core mission of the university is social good, through education, scholarship and relationships with the outside world,” Steve Caddick, professor of chemistry and UCL’s Vice-Provost (Enterprise) told Science|Business.

Read the full article >>